

ALLERGAN INC
Form 8-K/A
September 29, 2004

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

September 26, 2004

Date of Report (Date of earliest event reported)

ALLERGAN, INC.

(Exact name of registrant as specified in its charter)

Delaware

1-10269

95-1622442

(State of Incorporation)

(Commission File Number)

(IRS Employer
Identification Number)

**2525 Dupont Drive
Irvine, California 92612**

(Address of principal executive offices) (Zip Code)

(714) 246-4500

(Registrant's telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

**ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF
DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
SIGNATURES**

Table of Contents

This amendment updates the disclosure to Item 5 of the Current Report on Form 8-K filed by Allergan, Inc. (Allergan or the Company) on July 28, 2004.

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On July 28, 2004, Allergan announced that Trevor M. Jones, Ph.D. was appointed to its Board of Directors as a Class II director. On September 26, 2004, the Allergan Board of Directors voted to modify the class of director and term for Professor Jones. Professor Jones will now serve as a Class I director and his term will expire at Allergan's Annual Meeting of Stockholders in 2005.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALLERGAN, INC.

Date: September 28, 2004

By: /s/ Douglas S. Ingram

Name: Douglas S. Ingram

Title: Executive Vice President, General
Counsel and Secretary